Avacta is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group’s Affimer technology is a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. While Avacta has made considerable progress towards developing its own bio-therapeutics in 2016, two announcements recently have expanded its Affimer technology into new areas with large commercial potential. There remains a clear mismatch between the current EV and the long-term potential of Affimers.
